← Leaderboards
Ying Huang
Fred Hutchinson Cancer Center
$3,193,016
Attributed
$3,568,994
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $508.8K · FY2013–25$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,568,994 · 3
By mechanism
R01$2,817,037 · 2
U24$751,957 · 1
Top collaborators
- Ying Qing Chen2 shared
Most similar at Fred Hutchinson Cancer Center
Same institution · by research overlap
- Paul D Lampe$17,368,376
- A. McGarry Houghton$19,684,845
- Deborah J Donnell$179,670,738
- Cecilia C Yeung$2,137,399
- Evan Yu$8,305,807
Others in their field
Top investigators on “Algorithms”
- David Heimbrook · Leidos Biomedical Research, Inc.$112,814,417
- Randall J Bateman · Washington University$102,126,188
- Sharon L. Walsh · University Of Kentucky$81,731,115
- Eric S Lander · Whitehead Institute For Biomedical Res$71,530,862
- David H Walker · University Of Texas Medical Br Galveston$61,066,312
- Leonard Freedman · Leidos Biomedical Research, Inc.$46,756,756
Research focus
AlgorithmsBiological MarkersMalignant NeoplasmsDesignScreeningClinical PracticeDiagnosisProgramsResearch DesignLaboratoriesSamplingCharacteristicsCohortStatistical MethodsProceduresMalignant Neoplasm Of PancreasBaseEarly Detection Research NetworkAreaPhase 3 StudyScreening For CancerDissemination TrialBiomarker PerformanceBiomarker Panel
Grant awards (11)
Accelerating biomarker development through novel statistical methods for analyzing phase III/IV studies$401,719
R01 · FY2025 · CA · contact PI
Accelerating biomarker development through novel statistical methods for analyzing phase III/IV studies$381,633
R01 · FY2024 · CA · contact PI
Accelerating biomarker development through novel statistical methods for analyzing phase III/IV studies$413,415
R01 · FY2023 · CA · contact PI
2/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis$243,200
U24 · FY2021 · HL · contact PI
2/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis$1
U24 · FY2021 · HL · contact PI
2/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis$508,756
U24 · FY2020 · HL · contact PI
Statistical Methods for Selection and Evaluation of Biomarkers$323,434
R01 · FY2018 · GM · contact PI
Statistical Methods for Selection and Evaluation of Biomarkers$323,753
R01 · FY2017 · GM · contact PI
Statistical Methods for Selection and Evaluation of Biomarkers$324,063
R01 · FY2015 · GM · contact PI
Statistical Methods for Selection and Evaluation of Biomarkers$324,364
R01 · FY2014 · GM · contact PI
Statistical Methods for Selection and Evaluation of Biomarkers$324,656
R01 · FY2013 · GM · contact PI